UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Migraine
Abstract Introduction: Migraine is a primary headache disorder, which leads to diminished health‐related quality of life (HRQoL). There is limited…
Abstract Introduction: Migraine is a primary headache disorder, which leads to diminished health‐related quality of life (HRQoL). There is limited…
Abstract Introduction: Fibromyalgia is a common condition characterised by widespread chronic pain, associated with comorbid mental health disorders and reduced…
Abstract Background: Although there is growing evidence supporting the use of cannabis‐based medicinal products (CBMPs) for the management of chronic…
Abstract Background: Complex regional pain syndrome is characterized by severe, persistent pain. Emerging evidence suggests that cannabis‐based medicinal products may…
Abstract Insomnia affects approximately 10% of adults globally. Current treatments have their limitations, and there is growing evidence on the…
Abstract Objective: The study aims to evaluate the clinical outcomes in patients with hypermobility spectrum disorder (HSD) and hypermobile Ehlers–Danlos…
Abstract Introduction: Chronic pain (CP) affects 35.0%–51.3% of the UK population, with 67%–88% reporting sleep disturbances. Cannabis‐based medicinal products (CBMPs)…
Abstract Introduction: The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for…
Abstract This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety…
Abstract Background: Research on cannabis‐based medicinal products (CBMPs) in anxiety remains inconclusive due to a paucity of high‐quality evidence. Studies…